[go: up one dir, main page]

MX2007012947A - Bioenhanced compositions. - Google Patents

Bioenhanced compositions.

Info

Publication number
MX2007012947A
MX2007012947A MX2007012947A MX2007012947A MX2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A
Authority
MX
Mexico
Prior art keywords
arb
composition
solubility
solubility enhancing
present
Prior art date
Application number
MX2007012947A
Other languages
Spanish (es)
Inventor
Nagesh R Palepu
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Paras R Jain
Original Assignee
Rubicon Res Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Pvt Ltd filed Critical Rubicon Res Pvt Ltd
Publication of MX2007012947A publication Critical patent/MX2007012947A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. In particular, the present invention relates to solubility enhancing agents that not only act as solubility enhancers but also improve the dissolution rate particularly in acidic or mildly acidic media, where solubility of the ARB is minimal. In the composition, the ARB may be present in the form of physical blend, solid dispersion, solid solution or complex with the solubility enhancing agent. The composition of an ARB with solubility enhancing agent can be incorporated in an immediate release or a controlled release or any other suitable modified release formulation. Immediate release dosage forms containing the composition of an ARB give an in vitro release of at least 40% in acidic media (pH < 3). As a result, the bioavailability of the ARB can be increased by at least 20% as measured by Cmax, AUC0-t and AUCo-a??.
MX2007012947A 2005-04-18 2006-04-18 Bioenhanced compositions. MX2007012947A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN477MU2005 2005-04-18
IN315MU2006 2006-03-06
PCT/US2006/014422 WO2006113631A2 (en) 2005-04-18 2006-04-18 Bioenhanced compositions

Publications (1)

Publication Number Publication Date
MX2007012947A true MX2007012947A (en) 2008-04-09

Family

ID=37115820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012947A MX2007012947A (en) 2005-04-18 2006-04-18 Bioenhanced compositions.

Country Status (8)

Country Link
EP (1) EP1877042A4 (en)
JP (1) JP2008536929A (en)
KR (1) KR20080042039A (en)
AU (1) AU2006236497A1 (en)
CA (1) CA2605183A1 (en)
IL (1) IL186721A0 (en)
MX (1) MX2007012947A (en)
WO (1) WO2006113631A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123543A1 (en) * 2006-01-02 2009-05-14 Rubicon Research Private Limited Pharmaceutical compositions
CN101528224A (en) * 2006-09-05 2009-09-09 阿斯利康(瑞典)有限公司 Pharmaceutical composition comprising candesartan cilexetil
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
US20100041644A1 (en) * 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
MX2009005947A (en) * 2006-12-05 2009-06-17 Novartis Ag Microemulsion dosage forms of valsartan and methods of making the same.
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP2010535212A (en) * 2007-08-01 2010-11-18 テバ ファーマシューティカル インダストリーズ リミティド Improved candesartan formulation
CN101888829A (en) * 2007-10-09 2010-11-17 诺瓦提斯公司 Pharmaceutical preparations of valsartan
US20090143423A1 (en) * 2007-10-19 2009-06-04 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
JP5222550B2 (en) * 2007-12-27 2013-06-26 財團法人工業技術研究院 Sustained release composition and method for producing the same
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
BRPI0907151A2 (en) * 2008-02-28 2015-07-07 Novartis Ag Solid oral dosage forms of valsartan and methods of producing these forms
EP2285358A1 (en) * 2008-06-03 2011-02-23 Novartis AG Pulsatile release of valsartan
SI2165702T1 (en) 2008-09-17 2012-05-31 Helm Ag Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
WO2010151080A2 (en) * 2009-06-25 2010-12-29 진양제약 주식회사 Pharmaceutical composition containing carboxylosartan and a production method therefor
WO2011028016A2 (en) * 2009-09-04 2011-03-10 한올바이오파마주식회사 Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers
AU2013217013B2 (en) * 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
EP2928468A4 (en) * 2012-12-05 2016-07-27 Sawai Seiyaku Kk PREPARATION CONTAINING CANDÉSARTAN CILEXÉTIL
EP2952187A4 (en) 2013-01-30 2016-08-17 Sawai Seiyaku Kk PHARMACEUTICAL COMPOSITION CONTAINING CANDESARTAN CILEXETIL
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
JP7287955B2 (en) 2017-10-04 2023-06-06 セルジーン コーポレイション cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl] -1-methylcyclohexane-1-carboxamide compositions and methods of use
CN109350609A (en) * 2018-11-14 2019-02-19 常州大学 Preparation of chitosan-coated zein nanoparticles and application of loading acacetin sodium salt
CN113933472B (en) * 2020-06-29 2024-07-09 武汉武药科技有限公司 Dissolution medium for determining dissolution rate of telmisartan solid preparation and application thereof
CN112516105A (en) * 2020-12-10 2021-03-19 成都恒瑞制药有限公司 Losartan potassium oral preparation and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
JP3751287B2 (en) * 2002-03-27 2006-03-01 バイエル薬品株式会社 Miniaturized nifedipine nucleated tablets
CN1726030A (en) * 2002-12-18 2006-01-25 诺瓦提斯公司 Combinations of valsartan with cox-2 inhibitors
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin

Also Published As

Publication number Publication date
WO2006113631A3 (en) 2006-12-14
AU2006236497A1 (en) 2006-10-26
JP2008536929A (en) 2008-09-11
CA2605183A1 (en) 2006-10-26
IL186721A0 (en) 2008-02-09
EP1877042A2 (en) 2008-01-16
EP1877042A4 (en) 2011-03-02
KR20080042039A (en) 2008-05-14
WO2006113631A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
MX2007012947A (en) Bioenhanced compositions.
BRPI0910182A2 (en) compound of formula (i), pharmaceutical composition, method of treating a disorder and use of a compound &#34;
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
MX2010002191A (en) Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect.
UA104869C2 (en) Normal;heading 1;heading 2;heading 3;PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
UA107649C2 (en) Isoxazole-ligands of metabotropic glutamate receptor and their use as potentiator
UA95798C2 (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
MX2007013065A (en) Dihydrobenzofuran derivatives and uses thereof.
MX385798B (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
MX2009003246A (en) Analogs of ghrelin substituted at the n-terminal.
TW200626558A (en) Indazolone derivatives
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
DK2041133T3 (en) Derivatives of imadazole [1,2-A] pyridine-2-carboxamides, their preparation and their use in therapeutics
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
JO2852B1 (en) Anti-cancer compound and pharmaceutical composition comprising it
PL2120890T3 (en) Coated pellets
UA96994C2 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, method of the preparation and use thereof
ATE513820T1 (en) NEW BENZAMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
UA101627C2 (en) Normal;heading 1;heading 2;heading 3;COATING COMPOSITION COMPRISING POLYDEXTROSE, PROCESS FOR PREPARING SAME AND USE FOR COATING INGESTIBLE SOLID FORMS
UA122762C2 (en) ORAL COMPOSITION OF 9-[(2,2-DIMETHYLPROPYLAMINO)-METHYL]-MINOCYCLINE OR ITS SALTS, SOLID PRESSED DOSAGE FORM, COMPOSITION FOR INJECTIONS, APPLICATION AND METHOD OF PREPARATION OF THE PHARMACEUTICAL COMPOSITION
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
SI2165702T1 (en) Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation